Table 3.
Peptide
|
Inhibition of GH release, %*
|
||||
---|---|---|---|---|---|
Code | Dose | 0 min | 30 min | 60 min | 90 min |
JV-1-36 | 10 nM | 57 | 59 | 61 | 56 |
30 nM† | 100 | 100 | 100 | 100 | |
JV-1-38 | 10 nM | 46 | 53 | 51 | 54 |
30 nM† | 85 | 98 | 91 | 92 | |
JV-1-42 | 10 nM | 62 | 64 | 43 | 34 |
30 nM† | 97 | 91 | 82 | 76 | |
JV-1-50 | 30 nM | 38 | 34 | 25 | 11 |
JV-1-51 | 30 nM | 37 | 0 | 0 | 2 |
JV-1-52 | 30 nM | 72 | 5 | 4 | 4 |
JV-1-53 | 30 nM | 0 | 0 | 0 | 4 |
100 nM | 7 | 4 | 9 | 20 | |
PG 97-269 | 30 nM | 5 | 0 | 8 | 17 |
100 nM | 2 | 10 | 9 | 5 |
Calculated from NET INT of GH responses after the second infusion of 1 nM GHRH (NET INTGHRH = 1.0) and after simultaneous infusion of 1 nM GHRH and antagonist (NET INTGHRH+ANT) as 100 × (1.0-NET INTGHRH+ANT)/1.0.
†From ref. 16.